AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05016128
Drug: S-ketamine
RxNorm normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: S-ketamine is used for preventing postoperative hyperalgesia,thus reducing the patient's acute postoperative pain
Trial: NCT05016128
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline is used for control
Trial: NCT06290505
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure.
Trial: NCT05328843
Drug: PB119
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each subject received only one dose of study drug during the study period. After completing the pre-dose procedure on the morning of the first day of the study, the subjects were given a subcutaneous injection of PB-119 0.3 mL (150 μg) once in the abdomen by the study nurse. The actual time of administration will be recorded in the subject's eCRF.~Subjects should remain on an empty stomach for at least 10 hours prior to administration.
Trial: NCT04666961
Drug: Tamoxifen 20 mg
RxNorm normalized name: tamoxifen 20 MG
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
Trial: NCT04666961
Drug: Anastrozole 1Mg Tab
RxNorm normalized name: ANASTROZOLE 1MG TAB
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
Trial: NCT05145400
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab:10 mg/kg intravenous or 1400 mg subcutaneous (SC) via on-body delivery system (OBDS) will be administered in cycles 1-24.
Trial: NCT05145400
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR \> 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR \< 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death.
Trial: NCT05145400
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
Trial: NCT06661746
Drug: epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-based and epidural analgesia
Trial: NCT05662358
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection
Trial: NCT05662358
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
Trial: NCT05504330
Drug: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: First of all, ICAS patients were given health education to exhort them to reduce the risk factors of exposure to stroke and get rid of their unhealthy lifestyles. Secondly, for patients in need, standardize their dosage and course of treatment, mainly including antiplatelet drugs and statins. In addition, patients with diabetes and hypertension urge rational medication to control blood pressure and blood glucose level.
Trial: NCT05359627
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.
Trial: NCT04868968
Drug: DFV890
RxNorm normalized name: DFV890
DrugBank: DFV890 (DB16461)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of DFV890 film coated tablets twice daily (b.i.d.). for 3 days starting in the morning of Day 1 and 100 mg of DFV890 in the morning on the fourth day.
Trial: NCT03698162
Drug: Bevacizumab Injection
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be give to participants who have recurrent high-grade glioma as part of standard of care.
Trial: NCT05337267
Drug: sintilimab (after the change)
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3mg/kg，I.V.，single dose
Trial: NCT05337267
Drug: sintilimab (before the change)
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3mg/kg，I.V.，single dose
Trial: NCT00001101
Drug: ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06531720
Drug: Chlorhexidine Gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical preparation applied on oral mucosa lesion containing 0,2% CHX
Trial: NCT04744363
Drug: Stelara PFS
RxNorm normalized name: Stelara
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre filled syringes filled with AVT04 and Stelara
Trial: NCT04892654
Drug: Doravirine
RxNorm normalized name: Doravirine
DrugBank: Doravirine (DB12301)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor
Trial: NCT04892654
Drug: Dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antiretroviral, Integrase strand transfer inhibitors
Trial: NCT06535412
Drug: IMC-002 + SOC
RxNorm normalized name: IMC-18F1
DrugBank: Icrucumab (DB14824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg
Trial: NCT06095505
Drug: Alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib enteric-coated tablets
Trial: NCT04826692
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
Trial: NCT06681220
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion x 21 days each cycle
Trial: NCT05037760
Drug: KER-050 monotherapy
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KER-050 administered (SC) for up to 13 cycles. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
Trial: NCT05037760
Drug: KER-050 in combination with ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
Trial: NCT06625775
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive trastuzumab infusion (IV) or subcutaneous (SC)
Trial: NCT06209320
Drug: Lower dose atropine sulfate eye drops
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administer to eyes
Trial: NCT06209320
Drug: Low dose atropine sulfate eye drops
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administer to eyes
Trial: NCT05111561
Drug: BET Bromodomain Inhibitor ZEN-3694
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05111561
Drug: Binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04986631
Drug: Topiramate Tablets
RxNorm normalized name: Topiramate Tablets
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate intervention
Trial: NCT06336291
Drug: L19TNF
RxNorm normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 μg/kg
Trial: NCT06336291
Drug: L19TNF
RxNorm normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg/kg
Trial: NCT06336291
Drug: L19TNF
RxNorm normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 μg/kg
Trial: NCT06336291
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg/m2
Trial: NCT06336291
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 110 mg/m2
Trial: NCT04762277
Drug: Spesolimab - solution for infusion
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT04762277
Drug: Placebo matching spesolimab - solution for infusion
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT04762277
Drug: Spesolimab- solution for injection
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT04762277
Drug: Placebo matching to spesolimab- solution for injection
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT06684314
Drug: Efanesoctocog alfa
RxNorm normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
Trial: NCT06685289
Drug: Donafenib
RxNorm normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, oral, twice daily, continuous medication for 6 months
Trial: NCT05925621
Drug: Lecanemab
RxNorm normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational study
Trial: NCT06686797
Drug: PF-08049820
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution/suspension
Trial: NCT06627179
Drug: Intravitreal Injection of Ultevursen
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
DrugBank: Ultevursen (DB17835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 4 doses over a 24-month period
Trial: NCT06691685
Drug: ESO-T01 Injection
RxNorm normalized name: NY-ESO TCR therapeutic
DrugBank: Letetresgene autoleucel (DB17233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.
Trial: NCT06628310
Drug: ABBV-400
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT06628310
Drug: Budigalimab
RxNorm normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT06628310
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Infusion
Trial: NCT06235203
Drug: Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.
Trial: NCT04416451
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m\^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
Trial: NCT04416451
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~* Week 1: 100 mg~* Week 2: 200 mg~* Week 3: 400 mg~* Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
Trial: NCT06619860
Drug: VX-993
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT06619860
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT06619587
Drug: Phase I Arm A
RxNorm normalized name: magnesium aluminometasilicate type I-A
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
Trial: NCT06619587
Drug: Phase I Arm B
RxNorm normalized name: magnesium aluminometasilicate type i-b
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
Trial: NCT06623890
Drug: Omaveloxolone
RxNorm normalized name: Omaveloxolone
DrugBank: Omaveloxolone (DB12513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04864977
Drug: Basal Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants administered basal insulin
Trial: NCT06554613
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.
Trial: NCT06554613
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
Trial: NCT05026229
Drug: dasatinib plus consolidation chemotherapy with vincristine and prednisone
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
Trial: NCT04550546
Drug: Nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600,000 U/mL of nystatin in a rinse suspension
Trial: NCT06382493
Drug: Tegoprazan-containing sequential H. pylori eradication therapy
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy
Trial: NCT06382493
Drug: Esomeprazole-containing sequential H. pylori eradication therapy
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)
Trial: NCT04827056
Drug: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
RxNorm normalized name: dexmedetomidine Sublingual Product
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BXCL 501 40µg will be administered orally, as individual films in the SL space.
Trial: NCT04827056
Drug: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
RxNorm normalized name: dexmedetomidine Sublingual Product
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BXCL 501 80µg will be administered orally, as individual films in the SL space.
Trial: NCT04797013
Drug: rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
Trial: NCT04797013
Drug: rhTNK-tPA
RxNorm normalized name: tPA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
Trial: NCT05982873
Drug: ABBV-400
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT05092581
Drug: casirivimab+imdevimab
RxNorm normalized name: casirivimab / imdevimab
DrugBank: Imdevimab (DB15940)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose weight-based equivalent administered intravenously (IV)
Trial: NCT04650321
Drug: Ocrelizumab at home
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive ocrelizumab infusion at home.
Trial: NCT06679829
Drug: Siltuximab
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 11 mg/kg, will be administered seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).
Trial: NCT06679829
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2
Trial: NCT06681662
Drug: Ephedrine Hydrochloride 30 mg/ml
RxNorm normalized name: ephedrine hydrochloride 30 MG/ML
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg during induction.
Trial: NCT06681662
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 ml during induction.
Trial: NCT05696366
Drug: Sotagliflozin
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.
Trial: NCT05696366
Drug: Volagidemab
RxNorm normalized name: Volagidemab
DrugBank: Volagidemab (DB16421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
Trial: NCT04908137
Drug: 2-octyl cyanoacrylate
RxNorm normalized name: 2-octyl cyanoacrylate
DrugBank: 2-octyl cyanoacrylate (DB12040)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet No. 2. It is provided as a single use applicator in a blister package
Trial: NCT05894018
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg, orally, bid